INVA · Earnings event · Q2 2026 · archived
Innoviva (INVA) Q2 2026 earnings — TrendMatrix coverage
Reported · EPS $0.56 vs estimate $0.50 (+11.5%) — classified BEAT.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Event detail · Q2 2026
EPS beat/miss and revenue
| Metric | Estimate | Actual | Surprise |
|---|---|---|---|
| EPS (diluted) | $0.50 | $0.56 | +11.5% |
| Revenue (2026-06-30) | — | $119.6M | — |
Revenue source: xbrl.
Verdict reaction
How the verdict moved around this report
Before this report, TrendMatrix rated INVA Buy (Wait) at 6.5/10. After the Q2 2026 report, the verdict moved to Hold at 6.5/10.
Healthcare context
INVA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.53B
- P/E (fwd)
- 9.6
- P/E (ttm)
- 4.9
- 52-week range
- $16.52–$25.15
- Off 52-week high
- 15.7%
- RSI (14)
- 49
- Volume vs avg
- 0.66×
- Engine score
- 6.9/10
Live context at TrendMatrix’s latest engine read — updates after the report date; not frozen to it.